In this retrospective propensity score matching analysis, 19 matched patient pairs were analyzed from an original 38 CytoSorb treated patients and 105 non-CytoSorb treatment patients.  Patients with an interleukin-6 (IL-6) > 10,000 pg/ml were included who were treated from between October 2014 and May 2020. As noted by the authors, patients had a wide range of causes for their cytokine storm including septic shock, acute respiratory distress syndrome (ARDS), polytrauma, abdominal emergency, and solid organ transplant. To be included patients in the CytoSorb (CS therapy) group had to have received CytoSorb for at least 90 mins and only the first treatment cycle was included in the analysis, which meant comparing 0-12h before starting CS therapy with the status 12-24 hrs after starting CS therapy. Results showed that there was a significant reduction in IL-6 in patients with (p < 0.001) and without CS treatment (p = 0.005) and the median relative reduction with and without CS was 89% and 80% respectively. Furthermore, there was no significant difference in the relative change in C-reactive protein, lactate, or norepinephrine demand in either group and the in-hospital mortality was similar between groups (73.7%). This small, heterogenous study showed no difference in IL-6 reduction, hemodynamic stabilization, or mortality in patients with CytoSorb treatment compared to a matched patient population. Open-access publication: https://pubmed.ncbi.nlm.nih.gov/34292421/